Osmosis is considering a proposal to stop daily issuance of new OSMO tokens and pause the daily vesting of tokens to developers. If approved in the on-chain vote scheduled for October 20, 2026, the protocol's revenue would become the only source of staking rewards. The proposal also freezes about 51.9 million OSMO tokens currently held in vesting, requiring future governance approval for any release. This change would stop new token creation that currently offsets about 2% annual token burns, potentially impacting OSMO's supply dynamics and staking incentives.
The Osmosis proposal to end daily OSMO inflation and pause vesting is noted here with Pluang's market snapshot as of Oct 14, 2026 22:02 WIB: Among 50 major cryptocurrencies priced on Pluang, only 6 rose while 43 fell. Notable movers include LINK at Rp221.297 with a 1-day change of -5.21% and Pluang order activity showing 17% Sell / 83% Buy, ZIL at Rp59 with a 1-day change of -4.87% and 99% Sell / 1% Buy order activity, and XLM at Rp3.285 with a 1-day change of -4.76% and 34% Sell / 66% Buy order activity. The most notable figure is the 99% Sell order activity for ZIL.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
